January 2026 The U.S. Food and Drug Administration granted 510(k) clearance to Sublimed’s actiTENS mini, a portable transcutaneous electrical nerve and electrical muscle-stimulation device. Its cleared EMS applications include muscle re-education, prevention of disuse atrophy, increased local blood flow, temporary relaxation of muscle spasms, and maintenance or improvement of range of motion.
September 2025 Fasikl secured USD 26.5 million in Series B financing to accelerate the commercialization and continued development of its AI-powered neurostimulation therapies. The funding supports R&D, broader clinical applications, improved user experience, and expansion of the company’s therapeutic pipeline for essential tremor and other neurological movement disorders.
June 2025 UConn Health and Hartford HealthCare advanced plans to expand access to the Vivistim Paired Vagus Nerve Stimulation System for stroke rehabilitation. The proposed initiative included establishing a neuromodulation treatment center and providing stimulation-assisted occupational therapy to veterans experiencing upper-limb movement impairment after stroke.